Grafalon

Grafalon is a sterile solution for injection that contains anti‑T lymphocyte immunoglobulin (rabbit) as its active ingredient. It is a polyclonal antibody preparation classified as an immunosuppressant and is supplied in the European Union market for intravenous administration under prescription (Rx) status.

Grafalon is employed in clinical settings where modulation of the immune response is required. It is commonly used in the following contexts:

- Prevention of acute rejection in organ transplantation, particularly kidney and liver transplants. - Treatment of severe aplastic anemia as part of conditioning regimens. - Management of graft‑versus‑host disease (GVHD) following hematopoietic stem cell transplantation. - Induction therapy for certain autoimmune disorders when other treatments have failed. - As an adjunct in conditioning protocols prior to bone marrow transplantation.

Side effects of Grafalon vary in frequency and severity. They are typically categorized as follows:

Common: - Fever and chills during or after infusion. - Nausea, vomiting, or abdominal discomfort. - Transient hypertension or hypotension. - Mild rash or urticaria at the infusion site. - Elevated liver enzymes. - Fatigue or malaise.

Serious: - Severe allergic reactions including anaphylaxis. - Cytokine release syndrome with hypotension and respiratory distress. - Opportunistic infections due to profound immunosuppression. - Thromboembolic events such as deep‑vein thrombosis. - Hemolytic anemia or thrombocytopenia. - Renal impairment or acute kidney injury.

When considering Grafalon, clinicians should observe several precautionary measures. Important considerations include:

- Baseline assessment of infection risk; avoid use in active uncontrolled infections. - Monitor complete blood counts and liver/kidney function before and during therapy. - Screen for prior hypersensitivity to rabbit proteins or other immunoglobulin products. - Use with caution in patients with cardiovascular disease due to possible infusion‑related hemodynamic changes. - Evaluate for malignancy history, as profound immunosuppression may affect tumor surveillance. - Ensure appropriate vaccination status; live vaccines are contraindicated during treatment. - Discuss potential pregnancy and lactation implications with patients, as safety data are limited.

Grafalon may interact with other medications, influencing efficacy or safety. Interactions are generally grouped as:

Avoid: - Concurrent use of other potent immunosuppressants (e.g., alemtuzumab) without dose adjustment, due to additive immunosuppression. - Live viral vaccines administered during or shortly after therapy. - High‑dose corticosteroids that may exacerbate infection risk.

Use with caution: - Antimicrobial agents (e.g., antivirals, antifungals) that require dose modification in immunocompromised patients. - Anticoagulants, as infusion reactions can affect coagulation parameters. - Cytokine‑targeted therapies that may amplify cytokine release syndrome. - Drugs metabolized by the liver, given potential hepatic enzyme alterations.